CNS Pharmaceuticals Inc. Common Stock (CNSP)
Stock · NASDAQ · Health Care
$5.52as of 8/28/2026
Price chart
Open in TradingViewActive signals
Support level
$4.95
Industry
Biotechnology: Pharmaceutical Preparations
About CNSP
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblasto…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 8
- Website
- cnspharma.com/
Fundamentals
- 1-day range
- $5.19$5.38
- Market cap
- $7.65M
- P/E (trailing)
- —
- P/E (forward)
- -13.79
- EPS (trailing)
- $-29.17
- Dividend yield
- —
- Beta
- 1.05
- Avg. volume
- 38.0K
52-week range
$1.9$10.59
Forecasts
1 analyst ratings
Buy 86%
Hold 14%
Sell 0%
1-year price forecast
High
$10
+81.1%
Median
$10
+81.1%
Low
$10
+81.1%
CNS Pharmaceuticals Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- CNSPCNS Pharmaceuticals Inc. Common Stock$5.52▲ 0.11%Market cap $7.65MP/E —$1.9$10.59
- PCSAProcessa Pharmaceuticals Inc. Common Stock$2.07▼ 1.90%Market cap $7.65MP/E 3.31$1.67$14.24
- MTVAMetaVia Inc. Common Stock$1.71▲ 3.01%Market cap $7.49MP/E —$0.9661$19.03
- APREAprea Therapeutics Inc. Common stock$0.8387▼ 2.48%Market cap $7.83MP/E —$0.548$1.69
- APUSApimeds Pharmaceuticals US Inc. Common Stock$3.87▼ 1.28%Market cap $7.29MP/E —$3.39$403.1
- SNGXSoligenix Inc. Common Stock$0.38▲ 0.00%Market cap $8.24MP/E —$0.28$3.22
- XCURExicure Inc. Common Stock$1.34▼ 5.32%Market cap $8.60MP/E —$1.05$9.48
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CNSP CNS Pharmaceuticals Inc. Common Stock | $7.65M | — | $5.52 | ▲ 0.11% | $1.9$10.59 |
| PCSA Processa Pharmaceuticals Inc. Common Stock | $7.65M | 3.31 | $2.07 | ▼ 1.90% | $1.67$14.24 |
| MTVA MetaVia Inc. Common Stock | $7.49M | — | $1.71 | ▲ 3.01% | $0.9661$19.03 |
| APRE Aprea Therapeutics Inc. Common stock | $7.83M | — | $0.8387 | ▼ 2.48% | $0.548$1.69 |
| APUS Apimeds Pharmaceuticals US Inc. Common Stock | $7.29M | — | $3.87 | ▼ 1.28% | $3.39$403.1 |
| SNGX Soligenix Inc. Common Stock | $8.24M | — | $0.38 | ▲ 0.00% | $0.28$3.22 |
| XCUR Exicure Inc. Common Stock | $8.60M | — | $1.34 | ▼ 5.32% | $1.05$9.48 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- CNS Pharmaceuticals Q2 EPS $(0.38) Misses $(0.24) Estimatebenzinga · 8/12/2026
- CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic TransformationYahoo · 8/12/2026
- CNS Pharmaceuticals Q2 EPS $(0.38) Misses $(0.24) EstimateBenzinga · 8/12/2026
Insider Activity
Insider Actions →Acquired
26.1K
Disposed
0
- Faith L. Charles · May 18, 2026 · Buy7.1K @ $4.79
- Faulkner Eric · March 2, 2026 · Grant9.5K
- O'Loughlin Steve · March 2, 2026 · Grant9.5K
Institutional Ownership
March 31, 2026
- Total shares held
- 145.6K
- Total value held
- $348.7K
- Institutional holders
- 11
Top holders this quarter
- Unknown61.0K
- Unknown45.8K
- Unknown23.2K
- Unknown13.5K
- Unknown1.3K
- Unknown729
- Unknown8
- Unknown3
- Unknown1
- Unknown1
See the full, filterable feed with live charts on the MarketWall dashboard.